Powder: -20°C for 3 years | In solvent: -80°C for 1 year
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 243 | 现货 | ||
2 mg | ¥ 346 | 现货 | ||
5 mg | ¥ 587 | 现货 | ||
10 mg | ¥ 848 | 现货 | ||
25 mg | ¥ 1,810 | 现货 | ||
50 mg | ¥ 2,890 | 现货 | ||
100 mg | ¥ 4,330 | 现货 | ||
200 mg | ¥ 6,130 | 现货 | ||
500 mg | ¥ 8,930 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 646 | 现货 |
产品描述 | 3BDO is a new mTOR activator. 3BDO inhibits autophagy. |
体外活性 | Phosphorylation of RPS6KB1 and EIF4EBP1 is significantly increased by 3BDO with vector alone but suppressed with FKBP1A overexpression. Rapamycin fails to decrease the phosphorylation of MTOR and RPS6KB1 in the presence of 3BDO. 3BDO suppresses the increase in MAP1LC3B puncta induced with rapamycin. 3BDO also inhibits the effect of rapamycin in HUVECs. The phosphorylation of Ser residues is decreased in HUVECs treated with 10 μM rapamycin, and 60 μM 3BDO reverses the phosphorylation. The results show that 3BDO suppresses the increased MAP1LC3B puncta number, MAP1LC3B-II level and decreased SQSTM1 protein level induced by rapamycin. 3BDO could dose- and time-dependently decrease FLJ11812 level in HUVECs. Overexpression of FLJ11812 reverses the inhibition of autophagy induced by 3BDO[1]. |
体内活性 | Immunofluorescence assay reveals that 3BDO treatment increases the level of p-p70S6K and decreases the protein level of ATG13 in plaque endothelium of mice. 3BDO does not affect the phosphorylation of mTOR direct downstream targets p70S6K and 4EBP1. As compare with controls, apoE-/- mice show inhibited endothelium autophagy and apoptosis with 3BDO treatment, so 3BDO protects against endothelium injury in atherosclerosis. 3BDO treatment stabilizes established atherosclerotic lesions in apoE-/- mice. In apoE-/-mice, as compare with controls, with 3BDO treatment, the serum level of IL-6 and IL-8 is significantly decreased[2]. |
分子量 | 327.33 |
分子式 | C18H17NO5 |
CAS No. | 890405-51-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 150 mg/mL (458.25 mM)
Ethanol: 20 mg/mL (61.10 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 3.055 mL | 15.2751 mL | 30.5502 mL | 76.3755 mL |
5 mM | 0.611 mL | 3.055 mL | 6.11 mL | 15.2751 mL | |
10 mM | 0.3055 mL | 1.5275 mL | 3.055 mL | 7.6376 mL | |
20 mM | 0.1528 mL | 0.7638 mL | 1.5275 mL | 3.8188 mL | |
50 mM | 0.0611 mL | 0.3055 mL | 0.611 mL | 1.5275 mL | |
DMSO | 100 mM | 0.0306 mL | 0.1528 mL | 0.3055 mL | 0.7638 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
3BDO 890405-51-3 Apoptosis Autophagy PI3K/Akt/mTOR signaling mTOR Mammalian target of Rapamycin Inhibitor inhibit inhibitor